What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Predict response to immune checkpoint inhibition in acute myeloid leukemia (AML) using biomarkers
Naval G. Daver
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
The main challenges facing practitioners treating APL
Perspectives in AML treatment: targeting apoptosis without chemotherapy by using BH3-mimetics